Immuneering (IMRX) Enterprise Value (2020 - 2024)
Historic Enterprise Value for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to -$50.7 million.
- Immuneering's Enterprise Value rose 4790.58% to -$50.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$50.7 million, marking a year-over-year increase of 4790.58%. This contributed to the annual value of -$85.7 million for FY2023, which is 1881.94% up from last year.
- According to the latest figures from Q3 2024, Immuneering's Enterprise Value is -$50.7 million, which was up 4790.58% from -$59.7 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Enterprise Value ranged from a high of -$37.1 million in Q4 2020 and a low of -$149.5 million during Q3 2021
- For the 5-year period, Immuneering's Enterprise Value averaged around -$96.0 million, with its median value being -$97.2 million (2023).
- As far as peak fluctuations go, Immuneering's Enterprise Value tumbled by 30226.14% in 2021, and later soared by 4790.58% in 2024.
- Immuneering's Enterprise Value (Quarter) stood at -$37.1 million in 2020, then crashed by 302.26% to -$149.2 million in 2021, then increased by 29.27% to -$105.5 million in 2022, then grew by 18.82% to -$85.7 million in 2023, then skyrocketed by 40.87% to -$50.7 million in 2024.
- Its last three reported values are -$50.7 million in Q3 2024, -$59.7 million for Q2 2024, and -$71.3 million during Q1 2024.